

平成 30 (2018) 年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	相崎英樹	C 型肝炎ウイルスの遺伝子構造と抗ウイルス薬の作用機序は		日本医事新報	日本医事新報社	東京	2018	64-65	
2)	芥田憲夫、熊田博光	肝疾患治療薬-B 型・C 型肝炎における抗ウイルス療法・抗炎症療法	堀正二、菅野健太郎、門脇孝、乾賢一、林昌洋	治療薬ハンドブック 2018	(株)じほう	東京	2018	575-580	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M	Liver Cancer Study Group of Japan. Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey	Annals of Surgery	in press	doi: 10.1097/SLA.0000000000003192	2019	
2)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, <u>Tanaka J</u>	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic	Journal of Gastroenterology and Hepatology	in press	doi: 10.1111/jgh.14564	2019	
3)	Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, <u>Tanaka J</u> , Johnson PJ	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study	Liver International	39(3)	448-54, doi: 10.1111/liv.13987	2019	
4)	Nagashima S, Yamamoto C, Ko K, Chuon C, Sugiyama A, Ohisa M, Akita T, Katayama K, Yoshihara M, <u>Tanaka J</u>	Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination	Vaccine	37(1)	145-51, doi: 10.1016/j.vaccine.2018.11.019	2019	
5)	Yamamoto C, Ko K, Nagashima S, Harakawa T, Fujii T, Ohisa M, Katayama K, Takahashi K, Okamoto H, <u>Tanaka J</u>	Very low prevalence of anti-HAV in Japan: high potential for future outbreak	Scientific Reports	9(1)	1493, doi: 10.1038/s41598-018-37349-1	2019	
6)	Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, <u>Tanaka J</u> , Chayama K	Levodocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis	Hepatology Communications	22(3)	348-55, doi: 10.1002/hep4.1309	2019	
7)	<u>Tanaka J</u> , Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, Satake M	Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011	Journal of Viral Hepatitis	25(4)	363-72, doi: 10.1111/jvh.12828	2018	
8)	Kaishima T, Akita T, Ohisa M, Sakamune K, Kurisu A, Sugiyama A, Aikata H, Chayama K, <u>Tanaka J</u>	Cost-effectiveness analyses of anti-hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan	Hepatology Research	48(7)	509-20, doi: 10.1111/hepr.13053	2018	
9)	Yamasaki K, <u>Tanaka J</u> , Kurisu A, Akita T, Ohisa M, Sakamune K, Ko K, Sugiyama A, Yasaka T, Shirahama S	Natural course of persistent hepatitis B virus infection in HBe antigen-positive and -negative cohorts in Japan based on the Markov model	Journal of Medical Virology	90(12)	1800-13, doi: 10.1002/jmv.25260	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
10)	Toyoda H, Kumada T, Mizuno K, Hiraoka A, Tuji K, Ishikawa T, Akita T, Tanaka J	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias	Liver International	38(i12)	2260-8, doi: 10.1111/liv.13927	2018	
11)	Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments	Alimentary Pharmacology and Therapeutics	48(6)	664-70, doi: 10.1111/apt.14914	2018	
12)	Tada T, Kumada T, Toyoda H, Ohisa M, Akita T, Tanaka J	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model	Journal of Gastroenterology	53(11)	1196-205, doi: 10.1007/s00535-018-1467-x	2018	
13)	Uchida S, Satake M, Kurisu A, Sugiyama A, Ko K, Akita T, Tanaka J	Incidence Rates of Hepatitis C Virus Infection among Blood Donors in Japan: A Nationwide Retrospective Cohort Study	Transfusion	58(12)	2880-5, doi: 10.1111/trf.14951	2018	
14)	Lingani M, Akita T, Ouoba S, Sanou AM, Sugiyama A, Tarnagda Z, Ohisa M, Tinto H, Mishiro S, Tanaka J	High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies	BMC Public Health	18(1)	551, doi: 10.1186/s12889-018-5432-7	2018	
15)	Hirata F, Ishiyama K, Tanaka Y, Kobayashi T, Hashimoto M, Saeki Y, Ishida N, Taguchi K, Tanaka J , Arihiro K, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)	Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis	Annals of Gastroenterological Surgery	2(5)	383-93, doi: 10.1002/ags3.12195	2018	
16)	Matsumoto C, Shinohara N, Furuta RA, Tanishige N, Shimojima M, Matsubayashi K, Nagai T, Tsubaki K, Satake M .	Investigation of antibody to severe fever with thrombocytopenia syndrome virus (SFTSV) in blood samples donated in a SFTS-endemic area in Japan.	Vox Sang	113	297-299	2018	
17)	Furui Y, Yamagishi N, Morioka I, Taira R, Nishida K, Ohyama S, Matsumoto H, Nakamachi Y, Hasegawa T, Matsubayashi K, Nagai T, Satake M .	Sequence analyses of variable cytomegalovirus genes for distinction between breast milk- and transfusion-transmitted infections in very-low-birth-weight infants.	Transfusion	58	2894-2902	2018	
18)	Uchida S, Satake M , Kurisu A, Sugiyama A, Ko K, Akita T, Tanaka J	Incidence rates of hepatitis C virus infection among blood donors in Japan: a nationwide retrospective cohort study.	Transfusion	58	2880-2885	2018	○
19)	Tanaka J , Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, Satake M .	Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011	J Viral Hepat	25	363-372	2018	○
20)	Fukano K, Tsukuda S, Oshima M, Suzuki R, Aizaki H , Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K.	Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.	Front Microbiol	9		2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
21)	Takeuchi JS, Fukano K, Iwamoto M, Tsukuda S, Suzuki R, Aizaki H , Muramatsu M, Wakita T, Sureau C, Watashi K.	A Single Adaptive Mutation in Sodium Taurocholate Cotransporting Polypeptide Induced by Hepadnaviruses Determines Virus Species Specificity.	J Virol.		01432-18	2018	
22)	Ohashi H, Nishioka K, Nakajima S, Kim S, Suzuki R, Aizaki H , Fukasawa M, Kamisuki S, Sugawara F, Ohtani N, Muramatsu M, Wakita T, Watashi K.	The aryl hydrocarbon receptor-cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly.	J Biol Chem.	293	19559-19571	2018	
23)	Shirasago Y, Fukazawa H, Aizaki H , Suzuki T, Suzuki T, Sugiyama K, Wakita T, Hanada K, Abe R, Fukasawa M.	Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells.	J Gen Virol.	99	1407-1417	2018	
24)	Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, Ohki M, Ryo A, Park SY, Suzuki R, Aizaki H , Muramatsu M, Sureau C, Wakita T, Matano T, Watashi K.	A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction.	Biochem Biophys Res Commun.	22	374-379	2018	
25)	Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park SY, Suzuki R, Aizaki H , Ohtani N, Sureau C, Wakita T, Osada H, Watashi K.	Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.	Sci Rep.	8		2018	
26)	Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K	Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride	Hepatology Research	48(1)	45-50	2018	○
27)	Akuta N, Toyoda J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H.	Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/aunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection	J Gastroenterol	53(9)	1089-1097	2018	○
28)	Akuta N , Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	The complex association of virus-and host-related factors with HCC rate following HCV clearance.	J Clin Microbiol		doi:10.1128/JCM.01463-18	2018	○
29)	Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N , Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H	No-touch ablation in HCC has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.	Hepatology Res		doi:10.1111/hepr.13254	2018	
30)	Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N , Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.	J Gastroenterol		doi:10.1007/s00535-018-1502-y	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
31)	Takeuchi Y, <u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.	Hepatol Res		doi:10.1111/hepr.13242	2018	
32)	<u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antiviral regimens.	J Med Virol		doi:10.1002/jmv.25278	2018	○
33)	Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, <u>Akuta N</u> , Ito K, Kawamura M, Hiramatsu A, Sakamoto M, Harada K, Goto Y, Nakayama T, Kumada H, Okanoue T	Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study.	Hepatol Res		doi:10.1111/hepr.13226	2018	
34)	<u>Akuta N</u> , Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance.	J Med Virol	90(10)	1586-1592	2018	
35)	Kuwano T, <u>Akuta N</u> , Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H	A patient with HCV infection and a sustained virological response to direct-acting antiviral treatment who developed inclusion body myositis.	Intern Med	57(17)	2511-2515	2018	
36)	<u>Akuta N</u> , Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K	Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.	Hepatol Res	48(10)	810-813	2018	
37)	Ogata F, <u>Akuta N</u> , Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H	Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.	J Med Virol	90(6)	1087-1093	2018	○
38)	Ohya K, <u>Akuta N</u> , Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H	Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.	J Med Virol	90(5)	919-925	2018	○
39)	Ohya K, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kinowaki K, Fujii T, Kondo F, Kumada H.	Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases.	Hepatol Res		doi:10.1111/hepr.13295	2018	
40)	Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, <u>Akuta N</u> , Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.	Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study.	Liver Cancer	7(4)	323-334	2018	
41)	<u>Akuta N</u> , Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.	Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.	BMC Gastroenterol	18(1)	165	2018	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
42)	Ogasawara N, Kobayashi M, <u>Akuta N</u> , Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.	J Med Virol	90(2)	313-319	2018	○
43)	小林万利子、芥田憲夫、鈴木文孝、瀬崎ひとみ、鈴木義之、保坂哲也、小林正宏、斎藤聡、川村祐介、荒瀬康司、池田健次、熊田博光	HCV genotype1 または 2 以外の C 型慢性肝疾患における serological group の検討	肝臓	59 巻 8 号	437-438	2018	
44)	Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y1 Tomiyama Y, Kuribayashi F, <u>Torimura T</u> , Hino K.	Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.	Cellular and Molecular Gastroenterology and Hepatology	7	115-134	2019	
45)	Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, <u>Torimura T</u> .	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD.	Scientific reports	8	10434(p age.1-13).	2018	○
46)	Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Sakai M, Nomiyama M, Kuwano T, Tanaka M, Koga H, <u>Torimura T</u> .	Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.	Oncology			2018	
47)	Kawaguchi T, Nakano D, Oriishi T, <u>Torimura T</u> .	Effects of isomaltulose on insulin resistance and metabolites in patients with nonalcoholic fatty liver disease: A metabolomic analysis.	Molecular medicine reports	18	2033-2042	2018	
48)	Kawaguchi T, Nakano D, Koga H, <u>Torimura T</u> .	Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model.	Liver Cancer	in press		2018	
49)	Koya S, Kawaguchi T, Hashida R, Hirota K, Bekki M, Goto E, Yamada M, Sugimoto M, Hayashi S, Goshima N, Yoshiyama T, Otsuka T, Nozoe R, Nagamatsu A, Nakano D, Shirono T, Shimose S, Iwamoto H, Niizeki T, Matsuse H1, Koga H, Miura H, Shiba N, <u>Torimura T</u> .	Effects of In-Hospital Exercise on Sarcopenia in Hepatoma Patients Who Underwent Transcatheter Arterial Chemoembolization.	Journal of Gastroenterology and hepatology	in press		2018	
50)	Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, <u>Torimura T</u> , Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T; Miriplatin TACE Study Group.	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.	Journal of Gastroenterology	53	281-290	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
51)	Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, <u>Torimura T</u> , Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.	A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.	Journal of gastroenterology	in press		2018	
52)	Takahashi A, Arinaga-Hino T, Ohira H, Abe K, <u>Torimura T</u> , Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H.	Non-alcoholic fatty liver disease in patients with autoimmune hepatitis.	JGH open : an open access journal of gastroenterology and hepatology	2	54-58	2018	
53)	Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, <u>Torimura T</u> , Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N.	An analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan.	Hepatology research : the official journal of the Japan Society of Hepatology	in press		2018	
54)	Kawaguchi T, Inokuchi T, Honma T, Itano S, Kawasaki E, Inada C, Aoki T, Tsumura N, Araki A, Mukae T, <u>Torimura T</u> .	Factors Associated with Advanced Hepatic Fibrosis in Patients with Various Internal Diseases: A Multicenter Community-based Survey.	Hepatology Research	48	882-892	2018	
55)	Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, <u>Torimura T</u> , Saibara T, Kawaguchi A, Nakajima A, Eguchi Y; Japan Study Group for NAFLD (JSG-NAFLD).	Prevalence of pruritus in patients with chronic liver disease: a multicenter study.	Hepatology Research	48	E252-E262	2018	
56)	Arinaga-Hino T, Ide T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Nakamura T, Kawaguchi T, Koga H, Yonemoto K, <u>Torimura T</u> ; Kurume Autoimmune Hepatitis Study Group	Risk of malignancies in autoimmune hepatitis type 1 patients with a long-term follow-up in Japan.	Hepatology Research	48	E222-E231	2018	
57)	Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Guha IN, Kawaguchi T, <u>Torimura T</u> , McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J.	ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis.	Hepatology	in press		2018	
58)	Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, Hosaka K, Lim S, Wu J, He X, Sun X, Lu Y, Zhou Q, Shi W, <u>Torimura T</u> , Nie G, Li Q, Cao Y.	Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.	Cell metabolism	28	104-117	2018	
59)	Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, Nakamura T, Abe M, Masuda A, Sakaue T, Tanaka T, Kakuma T, Yano H, <u>Torimura T</u> .	High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.	Cancer science	109	2801-2810	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	Shota Okamoto, <u>Kazumi Yamasaki</u> , Atsumasa Komori, Seigo Abiru, Shinya Nagaoka, kira Saeki, Satoru Hashimoto, Shigemune Bekki, Hiroaki Okamoto, Hiroshi Yatsushashi	Dynamics of hepatitis B virus serum markers in an acute hepatitis B patient in the incubation phase	Clinical Journal of Gastroenterology		https://doi.org/10.1007/s12328-018-0925-6	2019	
61)	<u>Kazumi Yamasaki</u> , <u>Junko Tanaka</u> , <u>Akemi Kurisu</u> , <u>Tomoyuki Akita</u> , <u>Masayuki Ohisa</u> , <u>Kazuaki Sakamune</u> , <u>Ko Ko</u> , <u>Aya Sugiyama</u> , Takahiro Yasaka, Satoshi Shirahama	Natural course of persistent hepatitis B virus infection in hepatitis B e antigen-positive and hepatitis B e antigen-negative cohorts in Japan based on the Markov mode	Journal of Medical Virology	Volume 90, Issue 12	1785-1887	2018	○
62)	<u>Hino K</u> , Nishina S, Sasaki K, Hara Y.	Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection.	Free Radic Biol Med	in press		2018	
63)	Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, <u>Hino K</u>	Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice.	Cell Mol Gastroenterol Hepatol	7	115-34	2018	○
64)	Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, <u>Hino K</u>	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.	Hepatol Res	48	521-8	2018	○
65)	Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, <u>Hino K</u> , Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, Silius study group	Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.	Lancet Gastroenterol Hepatol	3	424-32	2018	○
66)	Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, <u>Hino K</u> , Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M	Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease.	Hepatol Commun	2	58-68	2018	○
67)	Sawai H, Nishida N, Khor SS, Honda M, Sugiyama M, Baba N, Yamada K, Sawada N, Tsugane S, Koike K, Kondo Y, Yatsushashi H, Nagaoka S, Taketomi A, Fukai K, Kurosaki M, Izumi N, Kang JH, Murata K, <u>Hino K</u> , Nishina S, Matsumoto A, Tanaka E, Sakamoto N, Ogawa K, Yamamoto K, Tamori A, Yokosuka O, Kanda T, Sakaida I, Itoh Y, Eguchi Y, Oeda S, Mochida S, Yuen MF, Seto WK, Poovorawan Y, Posuwan Y, Mizokami M, Tokunaga K	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma.	Sci Rep	8	7958	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
68)	Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.	J Gastroenterol	53	247-57	2018	○
69)	<u>Miyasaka A</u> , Yoshida Y, Yoshida T, Murakami A, Abe K, Ohuchi K, Kawakami T, Watanebe D, Hoshino T, Sawara K, Takikawa Y	The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C genotype 1.	Intern Med.	57	2807-2812	2018	○
70)	Yoshida Y, Yonezawa M, Okamoto T, Fujiwara Y, Suzuki A, Suzuki Y, Endo K, Kakisaka K, Oikawa T, Kuroda H, <u>Miyasaka A</u> , Takikawa Y	Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.	Clin J Gastroenterol.			2018	○
71)	Murai K, <u>Shimakami T</u> , Welsch C, Shirasaki T, Liu F, Kitabayashi J, Tanaka S, Funaki M, Omura H, Nishikawa T, Suminyadorj A, Honda M, Kaneko S.	Unexpected Replication Boost by Simeprevir for Simeprevir-resistant Variants in Genotype 1a Hepatitis C Virus. Antimicrob Agents Chemother	Antimicrob Agents Chemother	62	e02601-17	2018	○
72)	Shirasaki T, Honda M, Yamashita T, Nio K, <u>Shimakami T</u> , Shimizu R, Nakasyo S, Murai K, Shirasaki N, Okada H, Sakai Y, Sato T, Suzuki T, Yoshioka K, Kaneko S.	The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication	Sci Rep	8	13143	2018	○
73)	Miyazaki T, Nagasaka H, Komatsu H, Ayano Inui A, Morioka I, Tsukahara H, Kaji S, Hirayama S, Miida T, Kondou H, Ihara K, Yagi M, Kizaki Z, Bessho K, Kodama T, Iijima K, Yorifuji T, <u>Matsuzaki Y</u> , Honda A	Serum amino acid profiling in citrin-deficient children exhibiting normal liver function during the apparently healthy period	JIMD Rep	43	53-61	2019	
74)	Ra SG, TMiyazaki T, Kojima R, Komine S, Ishikura K, Kawanaka K, Honda A, <u>Matsuzaki Y</u> , Ohmori H	Effect of BCAA supplement timing on exercise-induced muscle soreness and damage: A pilot placebo-controlled double-blind study	J Sports Med Phys Fitness	58(11)	1582-1591	2018	
75)	Hirayama T, Ikegami T, Honda A, Miyazaki T, Yara S, Kohijima M, Nakamuta M, <u>Matsuzaki Y</u>	Difference of serum 4 β -hydroxycholesterol levels of patients with chronic HCV infection: A possible impact on the efficacy and safety of IFN-free treatment	Intern Med	57(9)	1219-1227	2018	
76)	Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, Monma T, Konishi N, Yara S, Hirayama T, Miyazaki T, Saito Y, Ikegami T, <u>Matsuzaki Y</u>	Detection of gut dysbiosis due to reduced clostridium subcluster IXVa using the fecal or serum bile acid profile	Inflamm Bowel Dis	24(5)	1035-1044	2018	
77)	Iwamoto J, Murakami M, Konishi N, Monma T, Ueda H, Yara S, Hirayama T, Ikegami T, Honda A, <u>Matsuzaki Y</u>	Effects of the concomitant use of low-dose clarithromycin with an anti-TNF α antibody in a patient with intestinal bechet disease	Intern Med	57(3)	339-342	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
78)	Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K	Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema	J Gastroenterol Hepatol	33(6)	1256-1263	2018	
79)	Asahina Y, Itoh Y, Ueno Y, <u>Matsuzaki Y</u> , Takikawa Y, Yatsuhashi H, Genda T, Ikeda F, Matsuda T, Dvory-Sobol H, Jiang D, Massetto B, Osinusi AO, Brainard DM, McHutchison JG, Kawada N, Enomoto N	Ledipasvir-Sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection	Liver International	38(9)	1552-1561	2018	
80)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, <u>Matsuzaki Y</u> , Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease	Hepatol Res	48(7)	549-555	2018	
81)	Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, Ohira H, Komori A, Yamagiwa S, Kikuchi K, Yasunaka T, Takaki A, Ueno Y, Honda A, <u>Matsuzaki Y</u> , Takikawa H	Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis	Sci Rep	8(1)	12542	2018	
82)	Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, <u>Matsuzaki Y</u> , Ohira H, Yoshiji H, Takikawa H; Japan PBC Study Group (JPBCSG)	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study	J Gastroenterol	53(10)	1151-1158	2018	
83)	Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, <u>Matsuzaki Y</u> , Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study	Hepatol Res		[Epub ahead of print]	2018	
84)	Miyazaki T, Honda A, Ikegami T, Iida T, <u>Matsuzaki Y</u>	Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model	J Clin Biochem Nutr		[Epub ahead of print]	2018	
85)	Miyazaki T, Sasaki S, Toyoda A, Shirai M, Ikegami T, <u>Matsuzaki Y</u> , Honda A	Influences of taurine deficiency on bile acids of the bile in the cat model	Adv Exp Med Biol		(in press)	2018	
86)	Suda G, Furusyo N, <u>Toyoda H</u> , Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamasaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N.	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.	Journal of Gastroenterology	53	119-128	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
87)	Hiraoka A, Kumada T, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Kawasaki H, Hiasa Y, Michitaka K.	erwent radiofrequency ablation: usefulness of albumin-bilirubin grade.	Hepatology Research	48	E61-E67	2018	
88)	Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouse K, <u>Toyoda H</u> , Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yomago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K.	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis.	Journal of Gastroenterology and Hepatology	34	436-441	2019	
89)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K.	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post-hoc analysis of a multicenter study.	Journal of Gastroenterology and Hepatology	34	364-369	2019	
90)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, <u>Toyoda H</u> , Kumada T, Goto H, Hirooka Y.	Utility and limitations of non-invasive fibrosis markers for predicting prognosis in biopsy-proven Japanese NAFLD patients.	Journal of Gastroenterology and Hepatology	34	207-214	2019	
91)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Hiasa Y, Michitaka K.	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis.	Hepatology Research	49	111-117	2019	
92)	Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Nakagawa-Iwashita A, Kondo C, Mikami S, Asano T, Matsuzaki Y, <u>Toyoda H</u> , Kumada T, Iio E, Tanaka Y, Iwakiri K.	Efficacy of direct-acting antivirals treatment in patients with compensated liver cirrhosis: a multicenter study.	Hepatology Research	49	125-135	2019	
93)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Sone Y, Akita Y, Tanaka J, Johnson PJ.	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study.	Liver International	39	448-454	2019	○
94)	Tada T, Kumada T, <u>Toyoda H</u> , Kobayashi N, Sone Y, Oguri T, Kamiyama N.	Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction.	American Journal of Roentgenology	212	332-341	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
95)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouse K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K.	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions – multicenter analysis.	Cancer Medicine	8	137-146	2019	
96)	Kariyama K, Nouse K, <u>Toyoda H</u> , Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M.	Utility of FIB-4-T as a prognostic factor for hepatocellular carcinoma.	Cancers (Basel)	11	E203	2019	
97)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K.	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.	Hepatology Research		in press		
98)	Tada T, Kumada T, <u>Toyoda H</u> , Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J.	Impact of ALBI grade on survival in patients with HCC who received sorafenib: an analysis using time-dependent ROC.	Journal of Gastroenterology and Hepatology		in press		○
99)	Nakashima M, <u>Toyoda H</u> , Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T.	Influence of renal dysfunction on dose reduction and virological efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection.	Hepatology Research		in press		
100)	Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VWS, Cheung R, Zhu Q, Nguyen MH.	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis of 237 studies and 13,044,518 individuals from 16 countries/regions.	Lancet Gastroenterology and Hepatology		in press		
101)	Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.	Alimentary Pharmacology and Therapeutics		in press		
102)	Takaguchi K, <u>Toyoda H</u> , Tsutui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H.	Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.	Journal of Gastroenterology		in press		

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
103)	Chuma M, <u>Toyoda H</u> , Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Takana K, Maeda S, Sakamoto N.	Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma.	Hepatology Research		in press		
104)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K.	Imaging basis of AFP and WFA+M2BP as indicators of the risk of HCC after SVR.	Journal of Hepatology	68	606-607	2018	○
105)	<u>Toyoda H</u> , Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Nostumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H.	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.	Hepatology	67	505-513	2018	
106)	Tada T, Kumada T, <u>Toyoda H</u> , Kobayashi N, Akita T, Tanaka J.	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers.	Journal of Gastroenterology and Hepatology	33	918-925	2018	○
107)	Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, <u>Toyoda H</u> , Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment or genotype 3 infection.	Journal of Gastroenterology	53	566-575	2018	
108)	<u>Toyoda H</u> , Kumada T, Tada T, Yama T, Mizuno K.	Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy.	Journal of Gastroenterology and Hepatology	33	1264-1270	2018	
109)	Shinkai N, Nojima M, Iio E, Matsunami K, <u>Toyoda H</u> , Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y.	High levels of Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.	Journal of Gastroenterology	53	883-889	2018	
110)	Tada T, Kumada T, <u>Toyoda H</u> , Saibara T, Ono M, Kage M.	New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.	Biomarkers	23	328-334	2018	
111)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, <u>Toyoda H</u> , Kumada T, Iio E, Tanaka Y, Iwakiri K.	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease.	Hepatology Research	48	549-555	2018	
112)	Tada T, Kumada T, <u>Toyoda H</u> , Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J.	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy.	Alimentary Pharmacology and Therapeutics	47	1012-1022	2018	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
113)	Okubo T, Atsukawa M, Tsubota A, <u>Toyoda H</u> , Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K	Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.	Hepatology International	12	133-142	2018	
114)	Tada T, Kumada T, <u>Toyoda H</u> , Ohisa M, Akita T, Tanaka J.	Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model.	Journal of Gastroenterology	53	1196-1205	2018	○
115)	Yasuda S, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, <u>Toyoda H</u> , Kumada T, Hirooka Y, Goto H.	Substitutions in interferon sensitivity determining region and hepatocarcinogenesis after hepatitis C virus eradication.	Journal of Gastroenterology and Hepatology	33	1904-1911	2018	
116)	<u>Toyoda H</u> , Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T.	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.	Journal of Gastroenterology	53	1276-1284	2018	
117)	Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, <u>Toyoda H</u> , Zhou MT.	A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection.	Clinica Chimica Acta	485	187-194	2018	
118)	Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y, <u>Toyoda H</u> , Kumada T, Hattori M, Katano Y, Goto H.	Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.	Journal of Viral Hepatitis	25	1446-1451	2018	
119)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J.	Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments.	Alimentary Pharmacology and Therapeutics	48	664-670	2018	○
120)	<u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Hiraoka A, Tsuji K, Ishikawa T, Akita T, Tanaka J.	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: a novel approach for the adjustment of lead time bias.	Liver International	38	2260-2268	2018	○
121)	Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, <u>Toyoda H</u> , Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M.	Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.	Hepatology International	12	356-367	2018	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
122)	Chan AWH, Zhong J, Berhane S, <u>Toyoda H</u> , Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, Garcia-Finana M, Kudo M, Kumada T, Roayaie S, Johnson PJ.	Prediction of early recurrence after surgical resection of hepatocellular carcinoma: an international collaborative study.	Journal of Hepatology	69	1284-1293	2018	
123)	Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, <u>Toyoda H</u> , Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.	Circulating let-7 levels in serum correlates with the severity of hepatic fibrosis in chronic hepatitis C.	Open Forum Infectious Diseases	5	ofy268	2018	
124)	Nobuhiro Ando, Keisuke Iwata, Kenji Yamazaki, Shogo Shimizu, <u>Junichi Sugihara</u> , Masaki Katayama, Hitoshi Iwata, Takuji Iwashita, Masahito Shimizu	A case of liver hilar tuberculous lymphadenitis complicated by biliary stricture diagnosed by endoscopic ultrasound-guided fine-needle aspiration	Clinical J of Gastroenterology	12		2018	
125)	清水省吾、山下晃司、杉原潤一、中野達徳、高橋雅春、長嶋茂雄、岡本宏明	化学療法の経過中に血小板減少を伴う E 型肝炎を発症し、肝炎治癒後の Nivolumab 治療により重篤な血小板減少症を併発した進行胃癌の 1 例	肝臓	59(9)	497 - 500	2018	
126)	山崎健路、山下晃司、九嶋亮治、岩田仁、中西孝之、永野淳二、安藤暢洋、杉原潤一、清水雅仁	黒色便を契機に診断された胃ラントラン沈着症の 1 例	Gastroenterological Endoscopy	60	215-222	2018	
127)	中野達徳、岡野 宏、西垣洋一、鈴木祐介、富田栄一、小林真、山脇 真、清水省吾、山下晃司、杉原潤一、高橋和明、新井雅裕、高橋雅春、長嶋茂雄、岡本宏明	孤発例でありながら、HEV 遺伝子解析により感染源が同一と推測された中部地方発生の E 型肝炎の 3 組 6 症例	肝臓	59(12)	700-703	2018	

平成 29 (2017) 年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	山下真未、田中純子	肝疾患総論 疫学	佐々木裕	ここまでの肝臓病診療	中山書店 東京		2017	50-54	○
2)	相崎英樹、Zheng Xin、脇田隆字	特集ウイルス肝炎のすべて		医学のあゆみ	医歯薬出版社	東京	2017	1215-1220	○
3)	相崎英樹、Zheng Xin、石井孝司、脇田隆字、砂川富正、大石和徳、吉岡健太郎	特集進化する B 型肝炎治療「B 型肝炎疫学の最新状況」		消化器・肝臓内科		東京	2017	390-397	○
4)	相崎英樹、和気健二郎、脇田隆字	ここまでのわかった C 型肝炎ウイルスの感染・複製機構、目覚しく治療効果を発揮する C 型肝炎治療		Mebio	メジカルビュー社	東京	2017	4-13	
5)	芥田憲夫	エルバスビルとグラゾプリルの併用療法	持田智	B 型・C 型肝炎の抗ウイルス療法	(株)医薬ジャーナル社	東京	2017	92-97	
6)	芥田憲夫、熊田博光	肝疾患治療薬-B 型・C 型肝炎における抗ウイルス療法・抗炎症療法	堀正二、菅野健太郎、門脇孝、乾賢一、林昌洋	治療薬ハンドブック 2017	(株)じほう	東京	2017	575-580	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Fujimoto M, Chuon C, Nagashima S, Yamamoto C, Ko K, Svay S, Hok S, Lim O, Ohisa M, Akita T, Katayama K, Matsuo J, Takahashi K, Tanaka J	A seroepidemiological survey of the effect of hepatitis B vaccine and hepatitis B and C virus infections among elementary school students in Siem Reap province, Cambodia	Hepatology Research	48(3)	E172-E182	2018	
2)	Sugiyama A, Fujii T, Nagashima S, Ohisa M, Yamamoto C, Chuon C, Akita T, Matsuo J, Katayama K, Takahashi K, Tanaka J	Pilot study for hepatitis virus screening among employees and effective approach to encourage screened positive employees to receive medical care in Japan	Hepatology Research	48(3)	E291-E302	2018	
3)	Fujii T, Ohisa M, Sako T, Harakawa T, Sakamune K, Nagashima S, Sugiyama A, Matsuura Y, Tanaka J	Incidence and risk factors of colorectal cancer based on 56,324 health checkups: 7 years retrospective cohort study	Journal of Gastroenterology and Hepatology	33(4)	855-862	2018	
4)	Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers	Journal of Gastroenterology and Hepatology	33(4)	918-925	2018	
5)	Iwasaki S, Shigeishi H, Akita T, Tanaka J , Sugiyama M	Efficacy of cognitive-behavioral therapy for patients with temporomandibular disorder pain-systematic review of previous reports	International Journal of Clinical and Experimental Medicine	11(2)	500-509	2018	
6)	Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, Wakahata A, Nakashima M, Nakamuta M, Tanaka J	Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting antiviral therapy	Alimentary Pharmacology & Therapeutics	47(7)	1012-1022	2018	
7)	Razavi-Shearer D, Gamkrelidze I, Nguyen M H, et al. (Tanaka J . 196 人中 175 番目)	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study	The LANCET Gastroenterology & Hepatology	in press	in press	2018	
8)	Mukaida K, Hattori N, Iwamoto H, Onari Y, Nishimura Y, Kondoh K, Akita T, Tanaka J , Kohno N	Mustard gas exposure and mortality among retired workers at a poisonous gas factory in Japan: A 57-year follow-up cohort study.	Occupational and Environmental Medicine	74(5)	321-327	2017	
9)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J	Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in CHB patients: an analysis using time-dependent ROC	Journal of Gastroenterology and Hepatology	32(2)	451-458	2017	
10)	Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J	Post-treatment levels of α -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C	Hepatology Research	47(10)	1021-1031	2017	
11)	Blach S, Zeuzem S, Manns M, et al. (Tanaka J . 222 人中 202 番目)	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study	The LANCET Gastroenterology & Hepatology	2(3)	161-176	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Sugiyama A, Ohisa M, Nagashima S, Yamamoto C, Chuon C, Fujii T, Akita T, Katayama K, Kudo Y, <u>Tanaka J</u>	Reduced prevalence of hepatitis B surface antigen positivity among pregnant women born after the national implementation of immunoprophylaxis for babies born to hepatitis B virus-carrier mothers in Japan	Hepatology Research	47(12)	1329-1334	2017	
13)	Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u>	Viral Eradication reduces all-Cause Mortality, Including non-Liver-Related Disease, in Patients With Progressive Hepatitis C Virus-Related Fibrosis.	J Gastroenterol Hepatol.	32(3)	687-694	2017	
14)	Matsuo J, Do SH, Yamamoto C, Nagashima S, Chuon C, Katayama K, Takahashi K, <u>Tanaka J</u>	Clustering infection of hepatitis B virus genotype B4 among residents in Vietnam, and its genomic characters both intra- and extra-family	PLOS ONE	12(7)	e0177248	2017	
15)	Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, <u>Tanaka J</u>	Differences in the impact of prognostic factors for hepatocellular carcinoma over time	Cancer Science	108(12)	2438-2444	2017	
16)	Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T, <u>Tanaka J</u>	Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease	Hepatology Communications	1(i9)	899-910	2017	
17)	<u>Tanaka J</u> , Akita T, Ohisa M, Sakamune K, Ko K, Uchida S, Satake M	Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011	Journal of Viral Hepatitis	25(4)	363-372	2017	
18)	Shoji K, Teishima J, Hayashi T, Shinmei S, Akita T, Sentani K, Takeshima Y, Arihiro K, <u>Tanaka J</u> , Yasui W, Matsubara A	A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients	Oncology Letters	14(1)	299-305	2017	
19)	杉山文、海嶋照美、坂宗和明、 <u>田中純子</u>	肝炎医療コーディネーターの活動実態調査研究—広島県および全国調査の結果から—	肝臓	59(1)	33-40	2018	
20)	杉山文、秋田智之、片山恵子、 <u>田中純子</u>	わが国の HBV 感染症の現状と展望	Mebio	35(1)	14-23	2018	
21)	秋田智之、 <u>田中純子</u>	肝癌の疫学	日本臨牀	76(2)	175-182	2018	
22)	<u>田中純子</u>	わが国における肝炎ウイルス感染者の動向	消化器・肝臓内科	3(3)	270-276	2018	
23)	<u>田中純子</u>	わが国の HCV 感染症の現状と展望	Mebio	34(1)	14-22	2017	
24)	<u>田中純子</u> 、片山恵子	C 型肝炎の疫学—最近の動向	消化器・肝臓内科	1(1)	59-65	2017	
25)	<u>田中純子</u>	C 型肝炎の疫学	医学と薬学	74(5)	517-523	2017	
26)	海嶋照美、片山恵子、 <u>田中純子</u>	ウイルス性肝炎の最新疫学	保健師ジャーナル	73(6)	475-480	2017	
27)	<u>田中純子</u>	わが国における B 型肝炎・C 型肝炎ウイルスキャリアの現状	医学のあゆみ	262(14)	1221-1232	2017	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
28)	<u>Satake M</u> , Matsubayashi K, Hoshi Y, Taira R, Furui Y, Kokudo N, Akamatsu N, Yoshizumi T, Ohkohchi N, Okamoto H, Miyoshi M, Tamura A, Fuse K, Tadokoro K.	Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression.	Transfusion	57	280-288	2017	
29)	Iwamoto M, Cai D, Sugiyama M, Suzuki R, <u>Aizaki H</u> , Ryo A, Ohtani N, Tanaka Y, Mizokami M, Wakita T, Guo H, Watashi K.	Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication.	Sci Rep.	7		2017	
30)	Tsutsumi T, Okushin K, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, <u>Aizaki H</u> , Suzuki T, Matsuura Y, Koike K.	Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver.	PLoS One.	12		2017	
31)	Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, <u>Aizaki H</u> , Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T.	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.	Hepatology	65	1104-1116	2017	
32)	Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H	Portal vein thrombosis in liver cirrhosis: incidence, management and outcome.	BMC Gastroenterol	17(1)	112	2017	
33)	Kawamura Y, Ikeda K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H	Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intra-subsegmental recurrence of small and single hepatocellular carcinoma	Hepatol Res	47(10)	1008-1020	2017	
34)	<u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.	J Med Virol	89(7)	1248-1254	2017	○
35)	Sezaki H, Suzuki F, Hosaka T, <u>Akuta N</u> , Fujiyama S, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H	The efficacy and safety of dual oral therapy with daclatasvir and sofosbuvir for genotype 1b in Japanese real-life settings.	Liver Int	37(9)	1325-1333	2017	○
36)	Kawamura Y, Ikeda K, Arase Y, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H	New discriminant method for identifying the aggressive disease phenotype of non-alcoholic fatty liver disease.	Intern Med	56(12)	1459-1465	2017	
37)	Osawa M, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh, Arase Y, Suzuki F, Ikeda K, Kumada H.	Prognosis and of precursors hepatocellular carcinoma in elderly patients infected with hepatitis B virus.	J Med Virol	89(12)	2144-2148	2017	
38)	Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.	J Med Virol	89(2)	284-290	2017	○
39)	Ikeda K, Kawamura Y, Kobayashi M, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H	Direct acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma	Dig Dis Sci	62(10)	2932-2942	2017	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
40)	Kawamura Y,Ikeda K,Fujiyama S,Hosaka T,Kobayashi M,Saitoh S,Sezaki H,Akuta N,Suzuki F,Suzuki Y,Arase Y,Kumada H	Usefulness and limitation of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with 4 or less hepatocellular carcinoma nodules.	Hepatol Res	47(4)	338-346	2017	
41)	Akuta N,Watanabe C,Kawamura Y,Arase Y,Saitoh S,Fujiyama S,Sezaki H,Hosaka T,Kobayashi M,Kobayashi M,Suzuki Y,Suzuki F,Ikeda K,Kumada H	Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus:preliminary prospective study based on serial liver biopsies.	Hepatology communications	1(1)	46-52	2017	
42)	Kobayashi M,Suzuki F,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T,Akuta N,Suzuki Y,Saitoh S,Arase Y,Ikeda K,Kumada H.	Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.	J Med Virol	89(3)	476-483	2017	○
43)	Ikeda K,Kawamura Y,Kobayashi M,Fujiyama S,Sezaki H,Hosaka T,Akuta N, Saitoh S,Suzuki F,Suzuki Y,Arase Y,Kumada H	Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma	Hepatol Res	47(7)	632-640	2017	
44)	Suzuki F,Suzuki Y,Hosaka T,Sezaki H,Akuta N,Fujiyama S,Kawamura Y,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Muneta R,Suzuki Y,Kumada H.	Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.	J Gastroenterol	52(5)	641-651	2017	
45)	Hayashi T*,Saitoh S,Fukuzawa K,Tsuji Y,Takahashi J,Kawamura Y,Akuta N,Kobayashi M,Ikeda K,Fujii T,Miyati T,Kumada H	Noninvasive assessment of advanced fibrosis based on hepatic volume in patients with nonalcoholic fatty liver disease.	Gut Liver	11(5)	674-683	2017	
46)	Akuta N,Sezaki H,Suzuki F,Kawamura Y,Hosaka T,Kobayashi M,Saitoh S,Sezaki H,Akuta N,Suzuki F,Suzuki Y,Arase Y,Kumada H.	Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.	J Med Virol	89(1)	91-98	2017	○
47)	Ogata F,Kobayashi M,Akuta N,Osawa M,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T,Kobayashi M,Saitoh S,Suzuki Y,Suzuki F,Arase Y,Ikeda K.	Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease.	Oncology	93(2)	92-98	2017	○
48)	Osawa M, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kinowaki K, Fujii T, Fukusato T, Kondo F, Kumada H	Cholangiocellular carcinoma in a young patients who showed sustained virological response after treatment for hepatitis C virus infection.	Intern Med	56(22)	3033-3040	2017	
49)	小林万利子、芥田憲夫、鈴木文孝、瀬崎ひとみ、鈴木義之、保坂哲也、藤山俊一郎、小林正宏、斎藤聡、川村祐介、荒瀬康司、池田健次、熊田博光	NS5A-P32 欠失を検出した C 型慢性肝疾患 Genotype 1b における治療効果の検討	肝臓	58 巻 12 号	671-673	2017	
50)	Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, Takano Y, Ueno T, Koga H, George J, Shiba N, Torimura T.	Aerobic versus resistance exercise in non-alcoholic fatty liver disease: A systematic review.	Journal of Hepatology	66	142-152	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
51)	Kawaguchi T, Koga H, <u>Torimura T.</u>	Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C.	Current Hepatology Reports	16	317-325	2017	○
52)	Abe M, Yoshida T, Akiba J, Ikezono Y, Wada F, Masuda A, Sakaue T, Tanaka T, Iwamoto H, Nakamura T, Sata M, Koga H, Yoshimura A, <u>Torimura T.</u>	STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury.	World Journal of Gastroenterology	23	6833-6844	2017	
53)	Ochi T, Kawaguchi T, Nakahara T, Ono M, Noguchi S, Koshiyama Y, Munekage K, Murakami E, Hiramatsu A, Ogasawara M, Hirose A, Mizuta H, Masuda K, Okamoto N, Suganuma N, Chayama K, Yamaguchi M, <u>Torimura T.</u> , Saibara T.	Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS.	Scientific Reports	7	10146(p age.1-9)	2017	○
54)	Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, <u>Torimura T.</u> ; Kurume Liver Cancer Study Group of Japan.	Clinical effects and safety of intraarterial infusion therapy of cisplatin suspension in lipiodol combined with 5 fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra hepatic spread: A prospective cohort study.	Molecular and Clinical Oncology	7	1013-1020	2017	
55)	Takahashi A, Arinaga-Hino T, Ohira H, <u>Torimura T.</u> , Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Yonemoto K, Tanaka A, Takikawa H; Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan.	Autoimmune hepatitis in Japan: trends in a nationwide survey.	Journal of Gastroenterology	52	631-641	2017	
56)	Nguyen Canh H, Harada K, Ouchi H, Sato Y, Tsuneyama K, Kage M, Nakano M, Yoshizawa K, Takahashi A, Abe M, Kang JH, Koike K, Inui A, Fujisawa T, Takaki A, Arinaga-Hino T, <u>Torimura T.</u> , Suzuki Y, Fujiwara K, Zeniya M, Ohira H, Tanaka A, Takikawa H, Intractable Liver and Biliary Diseases Study Group of Japan.	Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients.	Journal of Clinical Pathology	70	961-969	2017	
57)	Kawaguchi T, Ueno T, Nogata Y, Hayakawa M, Koga H, <u>Torimura T.</u>	Wheat-bran autolytic peptides containing a branched-chain amino acid attenuate non-alcoholic steatohepatitis via the suppression of oxidative stress and the upregulation of AMPK/ACC in high-fat diet-fed mice.	International Journal of Molecular Medicine	39	407-414	2017	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
58)	Koya S, Kawaguchi T, Hashida R, Goto E, Matsuse H, Saito H, Hirota K, Taira R, Matsushita Y, Imanaga M, Nagamatsu A, Shirono T, Shimose S, Iwamoto H, Niizeki T, Kuromatsu R, Miura H, Shiba N, <u>Torimura T.</u>	Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease.	Hepatology Research	47	E22-E34	2017	
59)	Yoshida T, Akiba J, Matsui T, Nakamura K, Hisamoto T, Abe M, Ikezono Y, Wada F, Iwamoto H, Nakamura T, Koga H, Yamagishi SI, <u>Torimura T.</u>	Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice.	Digestive Diseases and Sciences	62	1527-1536	2017	
60)	Nakamura M, Nakata K, Matsumoto H, Ohtsuka T, Yoshida K, Tokunaga S, Hino K.	Acyl/free carnitine ratio is a risk factor for hepatic steatosis after pancreatoduodenectomy and total pancreatectomy.	Pancreatology	17	135-8	2017	
61)	Koyama N, Hata J, Sato T, Tomiyama Y, <u>Hino K.</u>	Assessment of hepatic fibrosis with superb microvascular imaging in hepatitis C virus-associated chronic liver diseases.	Hepatol Res	47	593-7	2017	
62)	Tamada T, Korenaga M, Yamamoto A, Higaki A, Kanki A, Nishina S, <u>Hino K.</u> , Ito K.	Assessment of clinical and magnetic resonance imaging features of de novo hypervascular hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging.	Hepatol Res	47	E152-60	2017	
63)	吉田雄一, 岡田洋平, 鈴木彰子, 宮坂昭生, 渡辺大亮, 大内健, 吉田俊巳, 小野寺美緒, 星野孝男, 熊谷一郎, 近藤公亮, 川上格, 石井基嗣, 八木千栄, 三浦達也, 滝川康裕.	高齢 C 型慢性肝疾患患者におけるダクラタスビル・アスナプレビル併用療法の治療効果と安全性に関する検討	日本高齢消化器病学会誌	19(2)	68-74	2017	
64)	Yamane D, Selitsky SR, <u>Shimakami T.</u> , Li Y, Zhou M, Honda M, Sethupathy P, Lemon SM.	Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants	Nucleic Acids Res	45	4743-4755	2017	○
65)	Wang X, Oishi N, <u>Shimakami T.</u> , Yamashita T, Honda M, Murakami S, Kaneko S.	Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.	World J Gastroenterol.	23	3252-3261	2017	○
66)	Suda T, <u>Shimakami T.</u> , Shirasaki T, Yamashita T, Mizukoshi E, Honda M, Kaneko S.	Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents.	J Hepatol.	67	1108-1111	2017	○
67)	Ishida K, <u>Shimakami T.</u> , Kaneko S.	The use of direct-acting antivirals in the treatment of elderly patients with hepatitis C Virus infection.	Nihon Ronen Igakkai Zasshi.	54	375-380	2017	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
68)	Funaki M, Kitabayashi J, <u>Shimakami T</u> , Nagata N, Sakai Y, Takegoshi K, Okada H, Murai K, Shirasaki T, Oyama T, Yamashita T, Ota T, Takuwa Y, Honda M, Kaneko S.	Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo.	Sci Rep.	7	16978	2017	
69)	Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C1, Mikami S, Asano T, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C	Hepatol Res	47(13)	1429-1437	2017	
70)	Miyazaki T, Nakamura Y, Ebina K, Mizushima T, Ra SG, Ishikura K, <u>Matsuzaki Y</u> , Ohmori H, Honda A	Increased N-acetyltaurine in the skeletal muscle after endurance exercise in rat	Adv Exp Med Biol	975	403-411	2017	
71)	Higashimura Y, Baba Y, Inoue R, Takagi T, Mizushima K, Ohnogi H, Honda A, <u>Matsuzaki Y</u> , Naito Y	Agaro-oligosaccharides regulate gut microbiota and adipose tissue accumulation in mice	J Nutr Sci Vitaminol (Tokyo)	63(4)	269-276	2017	
72)	宮崎照雄, 池上正, 本多彰, <u>松崎靖司</u>	連載【各都道府県における肝臓疾患対策取り組みの現状】茨城県における肝臓疾患対策取り組みの現状.	肝臓クリニカルアップデート	3(1)	81-85	2017	○
73)	Tada T, <u>Kumada T</u> , Toyoda H, Saibara T, Ono M, Kage M	New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease	Biomarkers			2018	
74)	Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, <u>Matsuzaki Y</u> , Toyoda H, <u>Kumada T</u> , Iio E, Tanaka Y, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease	Hepatol Res			2018	
75)	Tada T, <u>Kumada T</u> , Toyoda H, Tsuji K, Hiraoka A, <u>Tanaka J</u> .	Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.	J Gastroenterol Hepatol.	32	451-458	2017	○
76)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J.	Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.	J Gastroenterol Hepatol.	32	687-694	2017	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
77)	Toyoda H, Tada T, Tachi Y, Hirai T, Yasuda S, Honda T, Hayashi K, Ishigami M, Goto H, <u>Kumada T</u>	Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.	Antivir Ther	22	185-193	2017	
78)	Toyoda H, <u>Kumada T</u> , Tada T	Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.	Hepatology	64	1818-1819	2017	
79)	Rho JH, Ladd JJ, Li CI, Potter JD, Zhang Y, Shelley D, Shibata D, Coppola D, Yamada H, Toyoda H, Tada T, <u>Kumada T</u> , Brenner DE, Hanash SM, Lampe PD	Protein and glycomic plasma markers for early detection of adenoma and colon cancer.	Gut			2017	
80)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka I</u>	Post-treatment levels of α -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.	Hepatol Res.	47	1021-1031	2017	○
81)	Toyoda H, <u>Kumada T</u> , Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B	J Hepatol.	66	521-527	2017	○
82)	Toyoda H, Tada T, Takaguchi K, Senoh T, Shimada N, Hiraoka A, Michitaka K, Ishikawa T, <u>Kumada T</u>	Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.	J Viral Hepat.	24	472-476	2017	
83)	Tada T, <u>Kumada T</u> , Toyoda H, Mizuno K, Sone Y, <u>Akita T</u> , <u>Tanaka I</u>	Progression of Liver Fibrosis Is Associated With Non-Liver-Related Mortality in Patients With Nonalcoholic Fatty Liver Disease	HEPATOLOGY COMMUNICATIONS	1	899-910	2017	
84)	Honda T, Ishigami M, Ishizu Y, Kuzuya T, Hayashi K, Ishikawa T, Murakami Y, Iwadate M, Umeyama H, Toyoda H, <u>Kumada T</u> , Katano Y, Goto H, Hirooka Y	Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B.	Clin Microbiol Infect.	23	407.e1-407.e7	2017	
85)	Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, <u>Kumada T</u>	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.	Br J Cancer	116	441-447	2017	
86)	Inoue T, Hmwe SS, Shimada N, Kato K, Ide T, Torimura T, <u>Kumada T</u> , Toyoda H, Tsubota A, Takaguchi K, Wakita T, Tanaka Y	Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.	PLOS ONE	12	e0170667	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
87)	Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, MoF, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, <u>Kumada T</u> , Johnson PJ	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.	Br J Cancer	116	448-454	2017	
88)	Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, <u>Kumada T</u> , Namisaki T, Yoshiji H, Sakamoto N, Nakagawa M, Asahina Y, Kurosaki M, Izumi N, Enomoto N, Kusakabe A, Kajiwarra E, Itoh Y, Ide T, Tamori A, Matsubara M, Kawada N, Shirabe K, Tomita E, Honda M, Kaneko S, Nishina S, Suetsugu A, Hiasa Y, Watanabe H, Genda T, Sakaida I, Nishiguchi S, Takaguchi K, Tanaka E, Sugihara J, Shimada M, Kondo Y, Kawai Y, Kojima K, Nagasaki M, Tokunaga K, Tanaka Y	Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.	Gastroenterology	152	1383-1394	2017	
89)	Toyoda H, <u>Kumada T</u> , Tada T, Mizuno K, Kobayashi N, Inukai Y, Takeda A, Sone Y	Discrepant imaging findings of portal vein thrombosis with dynamic computed tomography and computed tomography during arterial portography in hepatocellular carcinoma: possible cause leading to inappropriate treatment selection.	Clin J Gastroenterol	10	163-167	2017	
90)	Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, <u>Kumada T</u> , Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan	Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.	J Gastroenterol	21		2017	
91)	Tada T, <u>Kumada T</u> , Toyoda H, Mizuno K, Sone Y, Kataoka S, Hashinokuchi S	Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response	J Gastroenterol Hepatol.	32	1982-1988	2017	
92)	Tada T, <u>Kumada T</u> , Toyoda H	Reply to: "HBV markers for HCC prediction: Three heads are better than two?"	J Hepatol	67	204-205	2017	
93)	Tada T, <u>Kumada T</u> , Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouse K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y	Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan.	Cancer Sci.	108	1414-1420	2017	
94)	Hiraoka A, <u>Kumada T</u> , Michitaka K, Toyoda H, Tada T, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S	Real-Life Practice Experts For Hepatocellular Carcinoma (HCC) (RELPEC) Study Group and The HCC 48 Group (HCC experts from 48 clinics). Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.	Mol Clin Oncol.	6	455-461	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
95)	Matsushima-Nishiwaki R, Toyoda H, Takamatsu R, Yasuda E, Okuda S, Maeda A, Kaneoka Y, Yoshimi N, <u>Kumada T</u> , Kozawa O	Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway	Biochim Biophys Acta.	1863	1629-1639	2017	
96)	Dengler M, Stauffer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, <u>Kumada T</u> , Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis	Oncotarget	8	46234-46248	2017	
97)	Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, <u>Kumada T</u> , Chayama K, Sakamoto N	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan	J Gastroenterol	53	119-128	2017	
98)	Toyoda H, <u>Kumada T</u> , Tada T	Hepatitis B Core-Related Antigen: A Possible Indicator for the Termination of Prophylactic Nucleos(t)ide Analogue Therapy in Patients After Immunosuppressive Therapy	Am J Gastroenterol	112	969-970	2017	
99)	Hiraoka A, <u>Kumada T</u> , Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouse K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics)	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications	Liver Cancer	6	204-215	2017	
100)	Toyoda H, Hiraoka A, Tada T, Michitaka K, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S, <u>Kumada T</u>	Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis	Ther Apher Dial	21	465-472	2017	
101)	Tada T, <u>Kumada T</u> , Toyoda H, Kobayashi N, <u>Akita T</u> , <u>Tanaka I</u>	Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers.	J Gastroenterol Hepatol			2017	○
102)	Toyoda H, <u>Kumada T</u> , Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, <u>Akita T</u> , <u>Tanaka I</u>	Differences in the impact of prognostic factors for hepatocellular carcinoma over time	Cancer Sci.	108	2438-2444	2017	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
103)	Kobayashi N, <u>Kumada T</u> , Toyoda H, Tada T, Ito T, Kage M, Okanoue T, Kudo M	Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients	Dig Dis	35	602-610	2017	
104)	Toyoda H, <u>Kumada T</u> , Tada T, Mizuno K	Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR	J Hepatol			2017	
105)	Toyoda H, <u>Kumada T</u> , Tada T, Yama T, Mizuno K	Significance of Day-1 Viral Response of Hepatitis C Virus in Patients with Chronic Hepatitis C Receiving Direct-acting Antiviral Therapy	J Gastroenterol Hepatol			2017	
106)	Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, <u>Kumada T</u> , Tanaka Y	High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues	J Gastroenterol			2017	
107)	K.Matsuura, H.Sawai, K.Ikeo, S.Ogawa, E.Iio, M.Isogawa, N.Shimada, A.Komori, H.Toyoda, T.Kumada, T.Namisaki, H.Yoshiji, N.Sakamoto, M.Nakagawa, Y.Asahina, M.Kurosaki, N.Izumi, N.Enomoto, A.Kusakabe, E.Kajiwara, Y.Itoh, T.Ide, A.Tamori, M.Matsubara, N.Kawada, K.Shirabe, E.Tomita, M.Honda, S.Kaneko, S.Nishina, A.Suetsugu, Y.Hiasa, H.Watanabe, T.Genda, I.Sakaida, S.Nishiguchi, K.Takaguchi, E.Tanaka, <u>I.Sugihara</u> , M.Shimada, Y.Kondo, Y.Kawai, K.Kojima, M.Nagasaki, K.Tokunaga, Y.Tanaka	Genome-wide association study identifies a TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus	Gastroenterology	152	1383-1394	2017	
108)	Yamada T, Nannya Y, Suetsugu A, Shimizu S, <u>Sugihara J</u> , Shimizu M, Seishima M, Tsurumi H	Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature.	Intern Med.	56(1)	115-118	2017	
109)	山崎健路, 山内貴裕, 九嶋亮治, 岩田仁, 中西孝之, 永野淳二, 安藤暢洋, <u>杉原潤一</u> , 荒木寛司, 清水雅仁	早期胃癌研究会症例 微小癌が併存し内反性発育した孤在性十二指腸 Peutz-Jeghers 型ポリープの 1 例	胃と腸	52	1610-1619	2017	

平成 28 (2016) 年度 研究成果の刊行に関する一覧表 【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1) 川上由育、茶山一彰、田中純子、西田ルリコ	各都道府県における肝疾患対策取り組みの現状「広島県における肝炎、肝臓対策に対する取り組み」		肝臓クリニカルアップデート	医学図書出版株式会社	東京	2016	2(1),101-105	○
2) 相崎英樹、脇田隆字	肝炎ウイルス検査のすすめ		くらしの豆知識	国民生活センター	東京	2016	200-201	○
3) 相崎英樹、脇田隆字	C型肝炎治療における新時代の幕開け、C型肝炎ウイルスの複製・増殖のメカニズム		医薬ジャーナル	医薬ジャーナル社	大阪	2016	67-70	○
4) 芥田憲夫、熊田博光	肝疾患治療薬-B型・C型肝炎における抗ウイルス療法・抗炎症療法	堀正二、菅野健太郎、門脇孝、乾賢一、林昌洋	治療薬ハンドブック 2016	(株)じほう	東京	2016	565-571	○
5) 芥田憲夫	αβ-TxBLP/αβ-TxBLP併用療法	田中篤	C型肝炎治療のためのDAAの使い方	(株)文光堂	東京	2016	79-83	
6) 松崎靖司	薬物性肝障害、病気とくすり 2016		薬局 2016 年増刊号	南山堂	東京都	2016	754-758	
7) 池上正、屋良昭一郎、松崎靖司、本多彰、宮崎照雄	消化器生活習慣病における酸化ステロールの意義、特集/胆汁酸研究の進歩と展望-これからのbreakthroughを目指して-	「肝胆膵」編集委員会	肝胆膵	アークメディア	東京都	2016	72(5): 815-822	
8) 岩本淳一、本多彰、村上昌、池上正、松崎靖司	炎症性腸疾患における脂質・胆汁酸代謝と腸管吸収障害、特集/胆汁酸研究の進歩と展望-これからのbreakthroughを目指して-	「肝胆膵」編集委員会	肝胆膵	アークメディア	東京都	2016	72(5): 827-831	
9) 市田隆文、渡辺光博、加川建弘、松崎靖司	座談会、胆汁酸研究の進歩と展望-これからのbreakthroughを目指して-。特集/胆汁酸研究の進歩と展望-これからのbreakthroughを目指して-	「肝胆膵」編集委員会	肝胆膵	アークメディア	東京都	2016	72(5) : 935-950	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Mukaida K, Hattori N, Iwamoto H, Onari Y, Nishimura Y, Kondoh K, Akita T, Tanaka J , Kohno N.	Mustard gas exposure and mortality among retired workers at a poisonous gas factory in Japan: A 57-year follow-up cohort study.	Occupational and Environmental Medicine	74	321-327	2017	
2)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J .	Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in CHB patients: an analysis using time-dependent ROC	Journal of Gastroenterology and Hepatology	32(2)	451-458	2017	○
3)	Yoshimura M, Ohura N, Tanaka J , Ichimura S, Kasuya Y, Hotta O, Kagaya Y, Sekiyama T, Tannba M, Suzuki N.	Soft silicone foam dressing is more effective than polyurethane film dressing for preventing intraoperatively acquired pressure ulcers in spinal surgery patients: the Border Operating room Spinal Surgery (BOSS) trial in Japan	International Wound Journal	In press	doi: 10.1111/iwj.12696	2017	
4)	Murakami E, Tsuge M, Hiraga N, Kan H, Uchida T, Masaki K, Nakahara T, Ono A, Miki D, Kawaoka T, Abe H, Imamura M, Aikata H, Ochi H, Hayes CN, Akita T, Tanaka J , Chayama K.	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones	Journal of Infection	72(1)	91-102	2016	○
5)	Asao T, Oki K, Yoneda M, Tanaka J , Kohno N.	Hypothalamic-pituitary-adrenal axis activity is associated with the prevalence of chronic kidney disease in diabetic patients	ENDOCRINE JOURNAL	63(2)	119-126	2016	
6)	Matsumoto M, Takeuchi K, Tanaka J , Tazuma S, Inoue K, Owaki T, Iguchi S, Maeda T.	Follow-up study of the regional quota system of Japanese medical schools and prefecture scholarship programmes: a study protocol	BMJ Open	6	e011165	2016	
7)	Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J .	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index	Journal of Gastroenterology	51(4)	380-389	2016	○
8)	Morimoto H, Ide K, Tanaka Y, Ishiyama K, Ohira M, Tahara H, Akita T, Tanaka J , Ohdan H.	Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation	Human Immunology	77(6)	456-63	2016	○
9)	Tada T, Kumada T, Toyoda H, Kirishima S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yamada T, Tanaka J .	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics	Journal of Hepatology	65(1)	48-56	2016	○
10)	Tada T, Kumada T, Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J .	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis	Liver International	36(6)	817-816	2016	○
11)	Hosoi T, Kohda T, Matsuzaki S, Ishiguchi M, Kuwamura A, Akita T, Tanaka J , Ozawa K.	Key role of HSP90 in leptin-induced STAT3 activation and feeding regulation	British Journal of Pharmacology	173(15)	2434-2445	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Harada Y, Akita T, Takenaka J, Nakamura-Kadohiro Y, <u>Tanaka J</u> , Kiuchi Y.	Reproducibility of optic disk evaluation in supine subjects with a Heidelberg Retina Tomograph II laser tomographic scanner	Clinical Ophthalmology	24(10)	1617-1622	2016	
13)	Muzembo BA, Akita T, Matsuoka T, <u>Tanaka J</u> .	Systematic review and meta-analysis of hepatitis C virus infection in the Democratic Republic of Congo.	Public Health	139	13-21	2016	○
14)	Matsuoka T, Sato T, Akita T, Yanagida J, Ohge H, Kuwabara M, <u>Tanaka J</u> .	High Vaccination Coverage among Children during Influenza A(H1N1)pdm09 as a Potential Factor of Herd Immunity	International Journal of Environmental Research Public Health	13(10)	1017	2016	
15)	Shimomura M, Shinozaki K, Hinoi T, Yoshimitsu M, Kurayoshi M, Sumitani D, Ishizaki Y, Oshiro T, Kodama S, Shimizu Y, Arita M, Tokunaga M, Yoshida M, <u>Tanaka J</u> , Ohdan H; Hiroshima Surgical study group of Clinical Oncology (HiSCO).	A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study	Springerplus	5(1)	1800	2016	○
16)	Akita T, <u>Tanaka J</u> , Ohisa M, Sugiyama A, Nishida K, Inoue S, Shirasaka T.	Predicting future blood supply and demand in Japan with a Markov model: application to the sex-age specific probability of blood donation.	Transfusion	56(11)	2750-2759	2016	
17)	<u>田中純子</u>	わが国の HCV 感染症の現状と展望	Mebio	34(1)	14-22	2017	○
18)	<u>田中純子</u> 、片山恵子	C 型肝炎の疫学-最近の動向	消化器・肝臓内科	34(1)	59-65	2017	○
19)	海嶋照美、藤井紀子、永島慎太郎、片山恵子、神山道信、大熊博、 <u>田中純子</u>	高感度 HBs 抗原測定試薬 (BLEIA 法)を用いた検出性能に関する評価	肝臓	57(1)	42-44	2016	○
20)	海嶋照美、藤井紀子、松岡俊彦、坂宗和明、永島慎太郎、山本周子、Chuon Channarena、山下真未、大和昌代、藤井紘子、Muzembo Basilua Andre、杉山文、大久真幸、秋田智之、片山恵子、 <u>田中純子</u>	肝炎ウイルス検査受検状況と検査後の医療機関受診率の検討—都道府県別にみた認識受検率と非認識受検率—	肝臓	57(12)	634-648	2016	○
21)	<u>田中純子</u>	初回献血者および健診受診者集団における HBs 抗原陽性率の現状	病原微生物検出情報 (月報)	37(8)	2-5	2016	○
22)	<u>田中純子</u>	ウイルス肝炎の最新疫学～肝炎対策と患者数の動向～	Pharma Medica	34(2)	9-13	2016	○
23)	<u>田中純子</u>	わが国における HBV 感染の疫学	臨床消化器内科	31(3)	261-268	2016	○
24)	<u>田中純子</u> 、杉山文、大久真幸、秋田智之	疫学的視点からみた肝炎ウイルス患者に関する現状と対策	臨床病理	64(4)	465-470	2016	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
25)	田中純子、大久真幸	わが国の HCV 感染の変遷と現状	臨床消化器内科	31(11)	1431-1436	2016	○
26)	Nakajima S, Watashi K, Ohashi H, Kamisuki S, Izaguirre-Carbonell J, Kwon AT, Suzuki H, Kataoka M, Tsukuda S, Okada M, Moi ML, Takeuchi T, Arita M, Suzuki R, <u>Aizaki H</u> , Kato T, Suzuki T, Hasegawa H, Takasaki T, Sugawara F, Wakita T.	Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.	J Virol.	29	9085-74	2016	
27)	Puig-Basagoiti F, Fukuhara T, Tamura T, Ono C, Uemura K, Kawachi Y, Yamamoto S, Mori H, Kurihara T, Okamoto T, <u>Aizaki H</u> , Matsuura Y.	Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation.	J Virol.	90	8464-77	2016	
28)	Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watashi K, <u>Aizaki H</u> , Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R.	Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus.	Sci Rep.	6		2016	
29)	Suzuki R, Saito K, Matsuda M, Sato M, Kanegae Y, Shi G, Watashi K, <u>Aizaki H</u> , Chiba J, Saito I, Wakita T, Suzuki T.	Single-domain intrabodies against hepatitis C virus core inhibit viral propagation and core-induced NFκB activation.	J Gen Virol.	97	887-92	2016	
30)	Kong L, Fujimoto A, Nakamura M, Aoyagi H, Matsuda M, Watashi K, Suzuki R, Arita M, Yamagoe S, Dohmae N, Suzuki T, Sakamaki Y, Ichinose S, Suzuki T, Wakita T, <u>Aizaki H</u> .	Prolactin Regulatory Element Binding Protein Is Involved in Hepatitis C Virus Replication by Interaction with NS4B.	J Virol.	90	3093-111	2016	
31)	<u>Akuta N</u> , Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H	Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.	BMC Gastroenterol	16(1)	141-150	2016	
32)	Kunimoto H, Ikeda K, Sorin Y, Fujiyama S, Kawamura Y, Kobayashi M, Sezaki H, Hosaka T, <u>Akuta N</u> , Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H	Long-term outcomes of hepatitis-C-infected patients achieving a sustained virological response and undergoing radical treatment for hepatocellular carcinoma.	oncology	90	167-175	2016	○
33)	<u>Akuta N</u> , Kobayashi M, Suzuki F, Sezaki H, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Liver fibrosis and body mass index predict hepatocarcinogenesis following eradication of hepatitis C virus RNA by direct-acting antivirals	oncology	91	341-347	2016	
34)	<u>Akuta N</u> , Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Ikeda K, Kumada H	Relationships between genetic variations of PNPLA3, TM6SF2 and Histological features of nonalcoholic fatty liver disease in Japan.	Gut Liver	10	437-445	2016	
35)	<u>Akuta N</u> , Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.	J Med Virol	88	506-511	2016	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
36)	Kawamura Y, Arase Y, Ikeda K, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Inao M, Mochida S, Kumada H	Effects of alcohol consumption on hepatocarcinogenesis in Japanese Patients with fatty liver disease.	Clinical Gastroenterology and Hepatology	14	597-605	2016	
37)	Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Kunimoto H, Sorin Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Komayashi M, Ikeda K, Kumada H.	Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.	Hepatology Int	10	647-656	2016	
38)	芥田憲夫、渡辺ちづる、川村祐介、荒瀬康司、齊藤聡、藤山俊一郎、瀬崎ひとみ、保坂哲也、小林正宏、小林万利子、鈴木義之、鈴木文孝、池田健次、熊田博光	SGLT2 阻害薬が糖尿病合併非アルコール性脂肪性肝疾患に及ぼす影響-連続肝生検診断に基づく前向き試験-	肝臓	57 巻 9 号	502-504	2016	○
39)	Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T.	Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.	Scientific Reports	6	35282 (page 1-10)	2016	
40)	Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T.	Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease.	Scientific Reports	6	28814 (page 1-11)	2016	
41)	Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K, Nakamura H, Hisatomi J, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Kuromatsu R, Torimura T; DAAs Multicenter Study Group.	Evaluation of resistance-associated substitutions in NS5A using direct sequence and cyclecleave method and treatment outcome with Daclatasvir and Asunaprevir for chronic hepatitis C genotype 1.	PLoS One	11	e0163884 (page 1-11)	2016	○
42)	Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T.	Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.	Oncotarget	7	64400-64409	2016	
43)	Torimura T, Iwamoto H, Nakamura T, Abe M, Ikezono Y, Wada F, Sakaue T, Masuda H, Hashimoto O, Koga H, Ueno T, Yano H.	Antiangiogenic and antitumor activities of aflibercept, a soluble VEGF receptor-1 and -2, in a mouse model of hepatocellular carcinoma.	Neoplasia	18	413-424	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
44)	Nakamura T, Koga H, Iwamoto H, Tsutsumi V, Imamura Y, Naitou M, Masuda A, Ikezono Y, Abe M, Wada F, Sakaue T, Ueno T, Ii M, Alev C, Kawamoto A, Asahara T, <u>Torimura T.</u>	Ex vivo expansion of circulating CD34+ cells enhances the regenerative effect on rat liver cirrhosis.	Molecular Therapy - Methods & Clinical Development	3	16025 (page 1-13)	2016	
45)	Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K, <u>Torimura T.</u>	The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis.	Molecular and Clinical Oncology	5	83-88	2016	
46)	Hisamochi A, Kage M, Ide T, Arinaga-Hino T, Amano K, Kuwahara R, Ogata K, Miyajima I, Kumashiro R, Sata M, <u>Torimura T.</u>	An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.	Journal of Gastroenterology	51	597-607	2016	
47)	Ueyama M, Nishida N, Korenaga M, Korenaga K, Kumagai E, Yanai H, Adachi H, Katsuyama H, Moriyama S, Hamasaki H, Sako A, Sugiyama M, Aoki Y, Imamura M, Murata K, Masaki N, Kawaguchi T, <u>Torimura T.</u> Hyogo H, Aikata H, Ito K, Sumida Y, Kanazawa A, Watada H, Okamoto K, Honda K, Kon K, Kanto T, Mizokami M, Watanabe S.	The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus.	Journal of Gastroenterology	51	370-379	2016	
48)	Okamura S, Sumie S, Tonan T, Nakano M, Satani M, Shimose S, Shirono T, Iwamoto H, Aino H, Niizeki T, Tajiri N, Kuromatsu R, Okuda K, Nakashima O, <u>Torimura T.</u>	Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma.	Digestive and Liver Disease	48	945-952	2016	
49)	Kawaguchi T, Suetsugu T, Ogata S, Imanaga M, Ishii K, Esaki N, Sugimoto M, Otsuayama J, Nagamatsu A, Taniguchi E, Itou M, Oriishi T, Iwasaki S, Miura H, <u>Torimura T.</u>	An association between dietary habits and traffic accidents in patients with chronic liver disease: A data-mining analysis.	Biomedical Reports	4	615-622	2016	
50)	Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, <u>Hino K.</u> Nishiguchi S.	Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria.	Hepatol Res	46	951-63	2016	○
51)	Matsunami K, Nishida N, Kaneko N, Ikeo K, Toyo-Oka L, Takeuchi H, Matsuura K, Tamori A, Nomura H, Yoshiji H, Imamura M, Masaki N, Hayakawa T, Ide T, Shimada N, Ikeda F, <u>Hino K.</u> Nishiguchi S, Okuse C, Nojiri S, Sawamoto K, Tokunaga K, Joh T, Tanaka Y.	Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.	PLoS One	11	e0164418	2016	
52)	Nakamura, M. Matsumoto, H. Nakashima, H. Ando, Y. Hirai, T. Yoshida, K. <u>Hino, K.</u>	L-Carnitine Supplementation Improved Hepatic Steatosis After Pancreatectomy	Pancreas	45	e7-9	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
53)	Nishida, N. Ohashi, J. Khor, S.S. Sugiyama, M. Tsuchiura, T. Sawai, H. <u>Hino, K.</u> Honda, M. Kaneko, S. Yatsuhashi, H. Yokosuka, O. Koike, K. Kurosaki, M. Izumi, N. Korenaga, M. Kang, J.H. Tanaka, E. Taketomi, A. Eguchi, Y. Sakamoto, N. Yamamoto, K. Tamori, A. Sakaida, I. Hige, S. Itoh, Y. Mochida, S. Mita, E. Takikawa, Y. Ide, T. Hiasa, Y. Kojima, H. Yamamoto, K. Nakamura, M. Saji, H. Sasazuki, T. Kanto, T. Tokunaga, K. Mizokami, M.	Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis	Sci Rep	6	24767	2016	
54)	Okamoto, K, Koda, M. Okamoto, T. Onoyama, T. Miyoshi, K. Kishina, M. Kato, J. Tokunaga, S. Sugihara, T. A. Hara, Y. <u>Hino, K.</u> Murawaki, Y.	A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model	PLoS One	11	e0154676	2016	
55)	Ueno D, Nakashima H, Higashida M, Yoshida K, <u>Hino K</u> , Irei I, Moriya T, Matsumoto H, Hirai T, Nakamura M.	Emergent laparoscopic cholecystectomy for acute acalculous cholecystitis revisited.	Surg Today	46	309-12	2016	
56)	Liu F, <u>Shimakami T</u> , Murai K, Shirasaki T, Funaki M, Honda M, Murakami S, Yi M, Tang H, Kaneko S.	Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems	Sci Rep	6	30939	2016	○
57)	Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Arak M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, <u>Matsuzaki Y</u> , Iwakiri K, Aizawa Y	Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin	Hepatol Res	46(5)	450-458	2016	
58)	Higashimura Y, Naito Y, Takagi T, Uchiyama K, Mizushima K, Ushiroda C, Ohnogi H, Kudo Y, Yasui M, Inui S, Hisada T, Honda A, <u>Matsuzaki Y</u> , Yoshikawa T	Protective effect of agaro-oligosaccharides on gut dysbiosis and colon tumorigenesis in high-fat diet-fed mice.	Am J Physiol Gastrointest Liver Physiol	310	G367-G375	2016	
59)	Kaneko S, Ikeda K, <u>Matsuzaki Y</u> , Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K	Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study	J Gastroenterol. 51(10):1011-21, 2016	51(10)	1011-21	2016	
60)	Aoki T, Iijima H, Tada T, <u>Kumada T</u> , Nishimura T, Nakano C, Kishino K, Shimono Y, Yoh K, Takata R, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S.	Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases.	J Gastroenterol	52(1)	104-112	2017	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
61)	Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, Yeo W, Mo F, Lai P, Chan SL, Tada T, Toyoda H, <u>Kumada T</u> .	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance.	Br J Cancer.	Epub ahead of print		2017	
62)	Toyoda H, <u>Kumada T</u> , Tada T, Kaneoka Y, Maeda A, Korenaga M, Mizokami M, Narimatsu H.	Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection.	Liver Int.	36(2)	293-301	2016	○
63)	Hiraoka A, <u>Kumada T</u> , Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D, Tsuji K; Hiroaki Nagamatsu, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group.	Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study.	Hepatol Res.	46(6)	521-8	2016	
64)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriya S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka I</u> .	Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index.	J Gastroenterol	51 (4)	380-9	2016	○
65)	Tada T, <u>Kumada T</u> , Toyoda H, Ito T, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otake K, Takahashi K.	Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma.	Ultrasound Med Biol.	41(12)	3070-78	2016	
66)	Toyoda H, Tada T, Tsuji K, Hiraoka A, Tachi Y, Itobayashi E, Takaguchi K, Senoh T, Takizawa D, Ishikawa T, <u>Kumada T</u> .	Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan.	Hepatol Res.	46(8)	734-42	2016	○
67)	Hiraoka A, <u>Kumada T</u> , Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H.	Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.	J Gastroenterol Hepatol.	31(5)	1031-6	2016	○
68)	Terashita K, Chuma M, Hatanaka Y, Hatanaka K, Mitsuhashi T, Yokoo H, Ohmura T, Ishizu H, Muraoka S, Nagasaka A, Tsuji T, Yamamoto Y, Kurauchi N, Shimoyama N, Toyoda H, <u>Kumada T</u> , Kaneoka Y, Maeda A, Ogawa K, Natsuizaka M, Kamachi H, Kakisaka T, Kamiyama T, Taketomi A, Matsuno Y, Sakamoto N.	ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.	Clin Pathol.	69(7)	593-9	2016	
69)	Chan AW, <u>Kumada T</u> , Toyoda H, Tada T, Chong CC, Mo FK, Yeo W, Johnson PJ, Lai PB, Chan AT, To KF, Chan SL.	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.	J Gastroenterol Hepatol.	31(7)	1300-6	2016	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
70)	Berhane S, Toyoda H, Tada T, <u>Kumada T</u> , Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.	Clin Gastroenterol Hepatol.	14(6)	875-886	2016	
71)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.	Liver Int.	36(6)	817-26	2016	○
72)	Tada T, <u>Kumada T</u> , Toyoda H, Sone Y, Kaneoka Y, Maeda A, Okuda S, Otobe K, Tsuji N.	Utility of combined gray-scale and perflubutane contrast-enhanced ultrasound for diagnosing early hepatocellular carcinomas: Comparison of well differentiated and distinctly nodular types.	Hepatol Res.	46(12)	1214-1225	2016	
73)	Toyoda H, <u>Kumada T</u> , Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y.	Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.	J Gastroenterol	51(7)	741-7	2016	
74)	Toyoda H, <u>Kumada T</u> , Tada T.	Response to 'WFA(+)-M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases'.	Liver Int.	36(4)	613	2016	
75)	Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, <u>Kumada T</u> , Johnson PJ.	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.	Br J Cancer.	114(7)	744-50	2016	○
76)	Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.	J Hepatol.	65(1)	48-56	2016	○
77)	Matsushima-Nishiwaki R, Toyoda H, Nagasawa T, Yasuda E, Chiba N, Okuda S, Maeda A, Kaneoka Y, <u>Kumada T</u> , Kozawa O.	Phosphorylated Heat Shock Protein 20 (HSPB6) Regulates Transforming Growth Factor- α -Induced Migration and Invasion of Hepatocellular Carcinoma Cells.	PLoS One.	11(4)	e0151907	2016	
78)	Lin SY, Toyoda H, <u>Kumada T</u> , Liu HF. Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan.	Molecular Evolution and Phylodynamics of Acute Hepatitis B Virus in Japan.	PLoS One.	11(6)	e0157103	2016	
79)	Tada T, <u>Kumada T</u> , Toyoda H, Tsuji K, Hiraoka A, <u>Tanaka J</u> .	Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in CHB patients: an analysis using time-dependent ROC.	J Gastroenterol Hepatol.	Epub ahead of print		2016	○

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
80) Hiraoka A, <u>Kumada T</u> , Nouse K, Tsuji K, Itobayashi E, Hirooka M, Kariyama K, Ishikawa T, Tada T, Toyoda H, Kawasaki H, Hiasa Y, Michitaka K.	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.	Oncology.	91(3)	153-61	2016	
81) Takada K, Ito T, <u>Kumada T</u> , Toyoda H, Tada T, Sone Y, Endo T, Tanaka K, Kitagawa H, Ichikawa K.	Extra-hepatic feeding arteries of hepatocellular carcinoma: An investigation based on intra-arterial CT aortography images using an angio-MDCT system.	Eur J Radiol.	85(8)	1400-6	2016	
82) Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Viral Eradication reduces all-Cause Mortality, Including non-Liver-Related Disease, in Patients With Progressive Hepatitis C Virus-Related Fibrosis.	J Gastroenterol Hepatol.	Epub ahead of print		2016	○
83) Toyoda H, Tada T, Tachi Y, Hirai T, Yasuda S, Honda T, Hayashi K, Ishigami M, Goto H, <u>Kumada T</u>	Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.	Antivir Ther.	Epub ahead of print		2016	○
84) Toyoda H, <u>Kumada T</u> , Tada T.	Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.	Hepatology.	64(5)	1818-1819	2016	○
85) Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Tachi Y, Ishikawa T, Katano Y, Yoshioka K, Toyoda H, <u>Kumada T</u> , Goto H, Hirooka Y.	Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.	J Gastroenterol.	51(11)	1081-1089	2016	
86) Tada T, <u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, <u>Tanaka J</u> .	Post-treatment levels of α -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.	Hepatol Res.	Epub ahead of print		2016	○
87) Toyoda H, <u>Kumada T</u> , Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T.	Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.	J Hepatol.	Epub ahead of print		2016	○

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
88) Toyoda H, Tada T, Takaguchi K, Senoh T, Shimada N, Hiraoka A, Michitaka K, Ishikawa T, <u>Kumada T.</u>	Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.	J Viral Hepat.	Epub ahead of print		2016	
89) Honda T, Ishigami M, Ishizu Y, Kuzuya T, Hayashi K, Ishikawa T, Murakami Y, Iwadate M, Umeyama H, Toyoda H, <u>Kumada T.</u> Katano Y, Goto H, Hirooka Y.	The Core I97L mutation in conjunction with P79Q is associated with persistent low HBVDNA and HBs antigen clearance in chronic hepatitis B patients.	Clin Microbiol Infect.	Epub ahead of print		2016	
90) 豊田 秀徳, <u>熊田 卓</u> , 多田 俊史	目指せ!C 型肝炎ウイルスの克服-肝がん制圧に向けての更なる挑戦-】 あくなき議論!高齢者は何歳まで治療すべきか? 発癌リスク・生命予後・費用対効果の観点から、	肝臓クリニカルアップデート	2 巻 1 号	Page45-50	2016	
91) 多田 俊史, <u>熊田 卓</u> , 豊田 秀徳, 水野 和幸	肝硬変のマネージメント-その進歩と課題-】 C 型肝炎に対する抗ウイルス療法 肝不全・肝癌への進展をどう抑制するか、	消化器の臨床	19 巻 3 号	Page209-215	2016	
92) <u>熊田 卓</u>	【こむら返りと漢方】 こむら返りに対する芍薬甘草湯の効果	漢方と最新治療	25 巻 2 号	Page91-95	2016	
93) 平岡 淳, <u>熊田 卓</u> , 糸林 詠, 辻 邦彦, 石川 達, 広岡 昌史, 狩山 和也, 能祖 一裕, 多田 俊史, 豊田 秀徳, 日浅 陽一, 道堯 浩二郎	新しい肝予備能評価・albumin-bilirubin(ALBI)-grade を用いた肝癌ラジオ波治療における予後予測 JIS スコア変法・ALBI-T スコアの有用性	肝臓	57 巻 7 号	Page312-319	2016	
94) 豊田 秀徳, <u>熊田 卓</u>	【C 型肝炎 SVR 後の肝発癌】 C 型肝炎 SVR 症例の長期予後	医学のあゆみ	259 巻 4 号	Page287-291	2016	○